An epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease

International Journal of Nephrology and Renovascular Disease

Volumn 7, Issue , 2014, Pages 271-280

  Levy, Adrian R ^a,b   Perkins, Robert M ^c   Johnston, Karissa M ^b   Sullivan, Sean D ^d   Sood, Vipan C ^e   Agnese, Wendy ^e   Schnitzler, Mark A ^f  

^a DALHOUSIE UNIVERSITY   (Canada)

^b ICON PLC   (United Kingdom)

^c GEISINGER HEALTH SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Mitsubishi Tanabe Pharma Development America   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Cost effectiveness; Decision model; Disease progression; End stage renal disease; Epidemiology; Policy analysis

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CIRCANNUAL RHYTHM; COHORT ANALYSIS; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; TIME OF DEATH; UNITED STATES;

EID: 84904018826     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S58074     Document Type: Article

References (27)

1. Weinstein MC, Toy EL, Sandberg EA, etal. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health. 2001; 4(5): 348-361.
2. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 5-Working with Markov processes. Med Decis Making. 1997; 17(2): 152-159.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009; 113: S1-130.
4. Tangri N, Stevens LA, Griffith J, etal. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011; 305(15): 1553-1559.
5. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001; 59(2): 702-709.
6. Silveiro SP, Friedman R, de Azevedo MJ, Canani LH, Gross JL. Five-year prospective study of glomerular filtration rate and albumin excretion rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients. Diabetes Care. 1996; 19(2): 171-174.
7. Hunsicker LG, Adler S, Caggiula A, etal. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997; 51(6): 1908-1919.
8. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000; 17(5): 479-500.
9. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012; 15(6): 843-850.
10. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res. 2002; 2(2): 99-108.
11. Gorodetskaya I, Zenios S, McCulloch CE, etal. Health-related quality of life and estimates of utility in chronic kidney disease 1. Kidney Int. 2005; 68(6): 2801-2808.
12. Bass EB, Wills S, Fink NE, etal. How strong are patients' preferences in choices between dialysis modalities and doses? Am J Kidney Dis. 2004; 44(4): 695-705.
13. Collins AJ, Foley RN, Herzog C, etal. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis. 2011; 57(1 Suppl 1): A8, e1-e526.
14. Collins AJ, Foley RN, Herzog C, etal. US Renal Data System 2011 Annual Data Report. Am J Kidney Dis. 2012; 59(1 Suppl 1): A7, e1-e420.
15. Perkins RM, Bucaloiu ID, Kirchner HL, Ashouian N, Hartle JE, Yahya T. GFR decline and mortality risk among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6(8): 1879-1886.
16. Schell JO, Da Silva-Gane M, Germain MJ. Recent insights into life expectancy with and without dialysis. Curr Opin Nephrol Hypertens. 2013; 22(2): 185-192.
17. Hoefield RA, Kalra PA, Baker P, etal. Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis. 2010; 56(6): 1072-1081.
18. Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol. 2006; 1(4): 874-884.
19. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002; 22(5): 417-430.
20. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009; 12(1): 80-87.
21. Hoerger TJ, Wittenborn JS, Segel JE, etal. A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences. Am J Kidney Dis. 2010; 55(3): 452-462.
22. Hoerger TJ, Wittenborn JS, Segel JE, etal. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis. 2010; 55(3): 463-473.
23. Agarwal R, Bunaye Z, Bekele DM, Light RP. Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol. 2008; 28(4): 569-575.
24. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1-Getting started. Med Decis Making. 1997; 17(2): 123-125.
25. National Kidney Foundation and the US Food and Drug Administration. GFR Decline as an Endpoint for Clinical Trials in CKD. Available from: https: //www.kidney.org/professionals/research/pdf/EndpointsConfRoster.pdf. Accessed February 22, 2014.
26. Bamberger M, Moore N, Lechat P. How to improve the clinical development paradigm and its division into phases I, II and III. Therapie. 2011; 66(4): 331-334.
27. Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy. 1997; 2(1): 26-30.